Need To Know: Analysts Just Made A Substantial Cut To Their Silence Therapeutics plc (NASDAQ:SLN) Estimates [Yahoo! Finance]
Silence Therapeutics Plc - American Depository Share (SLN)
Company Research
Source: Yahoo! Finance
made a major negative revision to their near-term (statutory) forecasts for the organization. Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting analysts have soured majorly on the business. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Following the latest downgrade, the six analysts covering Silence Therapeutics provided consensus estimates of US$12m revenue in 2026, which would reflect a painful 55% decline on its sales over the past 12 months. Losses are predicted to fall substantially, shrinking 37% to US$0.86 per share. Yet before this consensus update, the analysts had been forecasting revenues of US$19m and losses of US$0.56 per share in 2026. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also expecting losses per share to increase. View our latest analysis for Sil
Show less
Read more
Impact Snapshot
Event Time:
SLN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLN alerts
High impacting Silence Therapeutics Plc - American Depository Share news events
Weekly update
A roundup of the hottest topics
SLN
News
- Silence Therapeutics: Divesiran Targets High-Burden PV [Seeking Alpha]Seeking Alpha
- Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare ConferenceBusiness Wire
- Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business HighlightsBusiness Wire
- Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)Business Wire
- Silence Therapeutics (NASDAQ:SLN) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
SLN
Analyst Actions
- 9/16/25 - HC Wainwright
SLN
Sec Filings
- 11/14/25 - Form 4
- 11/14/25 - Form SCHEDULE
- 11/12/25 - Form 10-Q
- SLN's page on the SEC website